# Novartis Pays $2B to Move Past Its Own Failed Cancer Drug

- slug: novartis-pays-2b-to-move-past-its-own-failed-cancer-drug
- date: 2026-03-22
- category: Biotech & Life Sciences

The pharma giant is acquiring Synnovation's mutant-selective PI3Kα inhibitor SNV4818, a bet that precision targeting can solve the tolerability problems that have haunted its first-generation Piqray.

---